Featured Research

from universities, journals, and other organizations

FDA Gives Nod To Technion "Sleep Moustache"

Date:
January 30, 2001
Source:
American Society For Technion - Israel Institute Of Technology
Summary:
The Food and Drug Administration has approved a novel device that inexpensively and accurately screens for sleep apnea at home. Characterized by the temporary cessation of breathing during sleep, sleep apnea could affect as many as 18 million people in the United States alone, particularly men over the age of 35.

New York, New York and Haifa, Israel, January 29, 2001 -- The Food and Drug Administration has approved a novel device that inexpensively and accurately screens for sleep apnea at home. Characterized by the temporary cessation of breathing during sleep, sleep apnea could affect as many as 18 million people in the United States alone, particularly men over the age of 35.

The patient fastens the 4-inch long plastic strip to his upper lip before bed. Three tiny temperature sensors attached to the strip record when the patient stops breathing, which in a sleep apnea sufferer can happen 200 to 300 times a night. In the morning, the patient removes the strip and returns it to the doctor who reads the results directly from the built-in display. The device is powered by a tiny eight-hour battery.

SleepStrip™ was developed at the Sleep Research Laboratory at the Technion-Israel Institute of Technology in Haifa by renowned sleep expert Dr. Peretz Lavie and Noam Hadas, head of research and development for SLP, a sister company of the laboratory. Researchers in Germany, Belgium, France, Italy, Israel, Canada and the United States have used SleepStrip™ to successfully screen patients with sleep apnea after one-night tests.

"It's important to detect sleep apnea as soon as possible because it can be a precursor to hypertension, ischemic heart disease, heart attack and stroke," says Dr. Lavie, who heads the Technion Sleep Research Laboratory. "With SleepStrip™ we can scan entire segments of the population, such as severely obese people and those with high blood pressure."

The National Center on Sleep Disorders Research reports that as many as two to four percent of middle-aged American men and two percent of middle-aged American women suffer from sleep apnea. Only 10 percent of those with sleep apnea are actually diagnosed, according to the National Sleep Foundation. This may be due to lack of awareness of sleep apnea, as well as the inconvenience, lack of privacy, discomfort and expense of spending a night in a sleep lab, which can cost from $1,100 to $4,000. While the SleepStrip™ doesn't replace a night in a sleep clinic, the patent-pending device can identify patients who need to go to one.

Dr. Yosef Krespi, chairman of the Department of Otolaryngology at St. Luke's-Roosevelt Hospital in New York, has tested more than 50 of the devices and says patients are responding favorably to it.

"Patients find the SleepStrip™ convenient and easy to use," Dr. Krespi says. "Most people don't like to be tested in a sleep laboratory overnight, and most sleep labs are located in hospitals, making it even more inconvenient. This device is inexpensive, reliable, small and disposable."

The Technion Sleep Research Laboratory has signed a marketing and distribution agreement with Influ-ENT, an Israel-based manufacturer and distributor of medical equipment. SleepStrip™ is available by prescription or can be bought from Influ-ENT by calling 1-800-564-7077 from the U.S. or Canada.


Story Source:

The above story is based on materials provided by American Society For Technion - Israel Institute Of Technology. Note: Materials may be edited for content and length.


Cite This Page:

American Society For Technion - Israel Institute Of Technology. "FDA Gives Nod To Technion "Sleep Moustache"." ScienceDaily. ScienceDaily, 30 January 2001. <www.sciencedaily.com/releases/2001/01/010130072945.htm>.
American Society For Technion - Israel Institute Of Technology. (2001, January 30). FDA Gives Nod To Technion "Sleep Moustache". ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2001/01/010130072945.htm
American Society For Technion - Israel Institute Of Technology. "FDA Gives Nod To Technion "Sleep Moustache"." ScienceDaily. www.sciencedaily.com/releases/2001/01/010130072945.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins